Patents by Inventor Melvyn Little
Melvyn Little has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220048994Abstract: The invention relates to a trispecific antigen-binding molecule, wherein the antigen-binding molecule is at least tetravalent and comprises an antigen-binding site having specificity against a first antigen epitope, an antigen-binding site having specificity against a second antigen epitope and two antigen-binding sites having specificity against a third antigen epitope and its use a medicament for tumor therapy.Type: ApplicationFiled: November 3, 2021Publication date: February 17, 2022Inventors: Melvyn Little, Eugene Zhukovsky, Markus Eser, Michael Weichel, Thorsten Gantke, Uwe Reusch, Kristina Ellwanger, Fabrice Le Gall
-
Publication number: 20210024654Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).Type: ApplicationFiled: March 18, 2020Publication date: January 28, 2021Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
-
Patent number: 10626190Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).Type: GrantFiled: October 27, 2017Date of Patent: April 21, 2020Assignee: Amphivena Therapeutics, Inc.Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
-
Patent number: 10273309Abstract: This application describes binding proteins that specifically bind to EGFRvIII and multispecific binding proteins that specifically bind to EGFRvIII and CD3. Further described is a multispecific tandem diabody that binds to EGFRvIII and CD3. Further described are highly cytotoxic EGFRvIII/CD3 bispecific tandem diabody for recruiting T cells to specifically and potently kill several types of solid tumor cancer.Type: GrantFiled: February 4, 2016Date of Patent: April 30, 2019Assignee: AFFEMED GMBHInventors: Kristina Ellwanger, Uwe Reusch, Ivica Fucek, Stefan Knackmuss, Vera Molkenthin, Melvyn Little, Eugene Zhukovsky
-
Publication number: 20180346590Abstract: In one aspect, the present invention relates to an antigen-binding molecule specific for albumin and CD3 which may comprise two polypeptide chains, each polypeptide chain having at least four variable domains in an orientation preventing Fv formation and the two polypeptide chains are dimerized with one another thereby forming a multivalent antigen-binding molecule. On each of the two polypeptide chains the four variable domains may be arranged in the order VLA-VHB-VLB-VHA from the N-terminal to the C-terminal of the polypeptide. Compositions of the antigen-binding molecule and the methods of using the antigen-binding molecule or the compositions thereof for treatment of various diseases are also provided herein.Type: ApplicationFiled: June 6, 2018Publication date: December 6, 2018Inventors: Melvyn Little, Fabrice Le Gall
-
Publication number: 20180291113Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).Type: ApplicationFiled: October 27, 2017Publication date: October 11, 2018Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
-
Patent number: 10066015Abstract: The invention relates to a humanized CD3 binding site, which comprises (a) a variable heavy chain domain (VH) as depicted in SEQ ID NO:8 and a variable light chain domain (VL) as depicted in SEQ ID NO:3; or (b) a variable heavy chain domain (VH) as depicted in SEQ ID NO:9 and a variable light chain domain (VL) as depicted in SEQ ID NO:4, or c) a variable heavy chain domain (VH) as depicted in SEQ ID NO:7 and a variable light chain domain (VL) as depicted in SEQ ID NO:2; or (d) a variable heavy chain domain (VH) as depicted in SEQ ID NO:6 and a variable light chain domain (VL) as depicted in SEQ ID NO:1. The CD3 binding sites have an increased stability, while the binding affinity has been retained due to mutations at positions VH111 and VL49.Type: GrantFiled: August 6, 2015Date of Patent: September 4, 2018Assignee: Affirmed GmbHInventors: Eugene Zhukovsky, Melvyn Little, Stefan Knackmuss, Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Michael Weichel, Markus Eser, Fionnuala McAleese-Eser
-
Patent number: 9803029Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).Type: GrantFiled: November 10, 2015Date of Patent: October 31, 2017Assignee: AMPHIVENA THERAPEUTICS, INC.Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
-
Patent number: 9701750Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.Type: GrantFiled: April 20, 2015Date of Patent: July 11, 2017Assignee: Affimed GmbHInventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch
-
Publication number: 20170037128Abstract: The invention relates to a trispecific antigen-binding molecule, wherein the antigen-binding molecule is at least tetravalent and comprises an antigen-binding site having specificity against a first antigen epitope, an antigen-binding site having specificity against a second antigen epitope and two antigen-binding sites having specificity against a third antigen epitope and its use a medicament for tumor therapy.Type: ApplicationFiled: October 11, 2016Publication date: February 9, 2017Inventors: Melvyn LITTLE, Eugene ZHUKOVSKY, Markus ESER, Michael WEICHEL, Thorsten GANTKE, Uwe REUSCH, Kristina ELLWANGER, Fabrice LE GALL
-
Publication number: 20160361413Abstract: The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (?) and gamma (?) secretases and amyloid beta peptide (A?), and also relates to a method of reducing A? shedding. Furthermore, this invention extends to a compound for use in the treatment of AD, and also to a method of treating AD.Type: ApplicationFiled: May 10, 2016Publication date: December 15, 2016Applicant: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURGInventors: Stefan Franz Thomas Weiss, Katarina Jovanovic, Danielle Gonsavles, Bianca Da Costa Dias, Stefan Knackmuss, Uwe Reusch, Melvyn Little, Marc Saul Weinberg
-
Publication number: 20160194409Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).Type: ApplicationFiled: November 10, 2015Publication date: July 7, 2016Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
-
Patent number: 9365647Abstract: The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (?) and gamma (?) secretases and amyloid beta peptide (A?), and also relates to a method of reducing A? shedding. Furthermore, this invention extends to a compound for use in the treatment of AD, and also to a method of treating AD.Type: GrantFiled: September 19, 2012Date of Patent: June 14, 2016Assignee: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURGInventors: Stefan Franz Thomas Weiss, Katarina Jovanovic, Danielle Gonsavles, Bianca Da Costa Dias, Stefan Knackmuss, Uwe Reusch, Melvyn Little, Marc Saul Weinberg
-
Publication number: 20160152728Abstract: This application describes binding proteins that specifically bind to EGFRvIII and multispecific binding proteins that specifically bind to EGFRvIII and CD3. Further described is a multispecific tandem diabody that binds to EGFRvIII and CD3.Type: ApplicationFiled: February 4, 2016Publication date: June 2, 2016Inventors: Kristina ELLWANGER, Uwe REUSCH, Ivica FUCEK, Stefan KNACKMUSS, Vera MOLKENTHIN, Melvyn LITTLE, Eugene ZHUKOVSKY
-
Publication number: 20160039934Abstract: The invention relates to a humanized CD3 binding site, which comprises (a) a variable heavy chain domain (VH) as depicted in SEQ ID NO:8 and a variable light chain domain (VL) as depicted in SEQ ID NO:3; or (b) a variable heavy chain domain (VH) as depicted in SEQ ID NO:9 and a variable light chain domain (VL) as depicted in SEQ ID NO:4, or c) a variable heavy chain domain (VH) as depicted in SEQ ID NO:7 and a variable light chain domain (VL) as depicted in SEQ ID NO:2; or (d) a variable heavy chain domain (VH) as depicted in SEQ ID NO:6 and a variable light chain domain (VL) as depicted in SEQ ID NO:1. The CD3 binding sites have an increased stability, while the binding affinity has been retained due to mutations at positions VH111 and VL49.Type: ApplicationFiled: August 6, 2015Publication date: February 11, 2016Inventors: Eugene ZHUKOVSKY, Melvyn Little, Stefan Knackmuss, Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Michael Weichel, Markus Eser, Fionnuala Mcaleese-Eser
-
Publication number: 20160002333Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).Type: ApplicationFiled: March 9, 2015Publication date: January 7, 2016Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
-
Patent number: 9212225Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).Type: GrantFiled: March 9, 2015Date of Patent: December 15, 2015Assignee: AMPHIVENA THERAPEUTICS, INC.Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
-
Publication number: 20150225484Abstract: In one aspect, the present invention relates to an antigen-binding molecule specific for albumin and CD3 which may comprise two polypeptide chains, each polypeptide chain having at least four variable domains in an orientation preventing Fv formation and the two polypeptide chains are dimerized with one another thereby forming a multivalent antigen-binding molecule. On each of the two polypeptide chains the four variable domains may be arranged in the order VLA-VHB-VLB-VHA from the N-terminal to the C-terminal of the polypeptide. Compositions of the antigen-binding molecule and the methods of using the antigen-binding molecule or the compositions thereof for treatment of various diseases are also provided herein.Type: ApplicationFiled: April 27, 2015Publication date: August 13, 2015Inventors: Melvyn LITTLE, Fabrice LE GALL
-
Publication number: 20150218275Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.Type: ApplicationFiled: April 20, 2015Publication date: August 6, 2015Inventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch
-
Patent number: 9035026Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.Type: GrantFiled: May 26, 2006Date of Patent: May 19, 2015Assignee: Affimed GMBHInventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch